The Career Development Program supports young Investigators pursuing careers in translational lymphoma research and also supports established investigators who wish to refocus their work on lymphoma. This program supports two individuals per year and provides 1-2 years of support for each awardee. The program is co-ordinated by the Administrative Core with oversight from the Executive Committee and Advisory Board. The program has well-defined processes for candidate recruitment, and will continue its successful efforts to recruit women and minorities. Both MD and PhD trainees selected by this program will be able to take advantage of courses available through the Clinical Scientist Training Program at BCM and will have a strong group of mentors with broad translational expertiseOijr mentoring strategies enhance the training program by providing trainees with multiple mentors who possess complementary skills, and planning Individualized training schemes. Additionally, trainees have access to the SPORE cores (clinical research, biostatistics, cell processing and vector production) which provide them with unique expertise in cell and gene therapy and clinical research. In the last 4 years, 6 trainees have been supported by this program and all have subsequently obtained independent peer-reviewed funding;three are now Incorporated Into SPORE projects.
The goal of this program is to provide training in translational research In lymphoma, thereby Increasing the number of well qualified and trained investigators jn basic science, population science and clinical research who will contribute to improving lymphoma treatment.
|Nabekura, Tsukasa; Chen, Zhiying; Schroeder, Casey et al. (2018) Crk Adaptor Proteins Regulate NK Cell Expansion and Differentiation during Mouse Cytomegalovirus Infection. J Immunol 200:3420-3428|
|Shum, Thomas; Kruse, Robert L; Rooney, Cliona M (2018) Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther 18:653-664|
|Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34|
|McLaughlin, Lauren P; Rouce, Rayne; Gottschalk, Stephen et al. (2018) EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 132:2351-2361|
|McClain, Kenneth L; Picarsic, Jennifer; Chakraborty, Rikhia et al. (2018) CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 124:2607-2620|
|Gomes-Silva, Diogo; Ramos, Carlos A (2018) Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line. Biotechnol J 13:|
|Brunetti, Lorenzo; Gundry, Michael C; Kitano, Ayumi et al. (2018) Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. J Vis Exp :|
|Xiong, Wei; Chen, Yuhui; Kang, Xi et al. (2018) Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Mol Ther 26:963-975|
|Heslop, Helen E; Brenner, Malcolm K (2018) Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther 26:1-2|
|Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336|
Showing the most recent 10 out of 270 publications